FDA Expands Approval of AJOVY as First Anti-CGRP Preventive for Pediatric Episodic Migraine
In a significant development for pediatric migraine care, Teva Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for AJOVY…
Read More...
Read More...
